SPART (Spartin) encodes a protein involved in lipid droplet metabolism, mitochondrial function, and endosomal trafficking. Mutations in SPART cause autosomal recessive hereditary spastic paraplegia (SPG20), also known as Troyer syndrome. The protein is widely expressed and localizes to lipid droplets, mitochondria, and the cytoskeleton.
Spartin is a multifunctional protein that plays critical roles in cellular homeostasis, particularly in lipid metabolism, mitochondrial dynamics, and endosomal trafficking. The gene is located on chromosome 4p16.3 and encodes a protein of 628 amino acids with multiple functional domains. Loss-of-function mutations in SPART cause a progressive neurodegenerative disorder characterized by spastic paraplegia, developmental delay, and cognitive impairment[1].
| Attribute | Value |
|---|---|
| Symbol | SPART |
| Full Name | Spartin |
| Chromosomal Location | 4p16.3 |
| NCBI Gene ID | 55037 |
| OMIM | 607111 |
| Ensembl ID | ENSG00000133104 |
| UniProt ID | Q9UQ10 |
| Associated Diseases | Hereditary Spastic Paraplegia (SPG20), Troyer Syndrome |
Spartin is a 628-amino acid protein with several distinct functional domains:
The N-terminal region contains a microtubule-interacting domain that allows spartin to associate with the cytoskeleton. This domain is important for the protein's localization to cellular compartments and its role in intracellular trafficking[2].
The central region contains a conserved SPARTin-like domain that may be involved in protein-protein interactions. This domain shares homology with the spastin protein, another hereditary spastic paraplegia protein, suggesting functional overlap in cellular pathways[3].
The C-terminal region contains a lipid droplet-binding domain that targets spartin to lipid droplets. This domain is crucial for spartin's role in lipid metabolism and consists of multiple helical regions that mediate membrane association[4].
Spartin plays a critical role in the regulation of lipid droplet dynamics. Lipid droplets are cellular organelles that store neutral lipids and are essential for energy homeostasis, membrane synthesis, and cellular signaling.
Lipid Droplet Turnover: Spartin localizes to lipid droplets through its C-terminal binding domain and regulates their turnover through interaction with the autophagy machinery[5]. The protein facilitates the recruitment of autophagic machinery to lipid droplets, enabling their degradation during nutrient stress or cellular remodeling.
Lipid Droplet Distribution: Spartin affects the subcellular distribution of lipid droplets by promoting their movement along microtubules. This function is particularly important in cells with high lipid metabolism, such as hepatocytes and adipocytes.
Pathogenic Implications: In SPART-related hereditary spastic paraplegia, loss of spartin function leads to accumulation of lipid droplets in various tissues, including the brain. This lipid accumulation disrupts cellular homeostasis and contributes to neurodegeneration[6].
Spartin is localized to mitochondria and plays important roles in mitochondrial dynamics and quality control.
Mitochondrial Dynamics: Spartin interacts with mitochondrial fission machinery and regulates the balance between mitochondrial fission and fusion. Proper mitochondrial dynamics are essential for maintaining mitochondrial function, cellular energy metabolism, and cell survival[7].
Mitochondrial Quality Control: Through its role in mitophagy (mitochondrial autophagy), spartin helps eliminate damaged mitochondria. This quality control mechanism is particularly important in post-mitotic cells like neurons, which are highly dependent on mitochondrial function[8].
ATP Production: Spartin deficiency leads to impaired mitochondrial respiration and reduced ATP production. This energy deficit affects cellular function and contributes to neuronal dysfunction and death.
Calcium Handling: Mitochondrial calcium homeostasis is disrupted in spartin-deficient cells, leading to impaired calcium signaling and increased susceptibility to excitotoxicity.
Spartin participates in endosomal trafficking and sorting, functions that are essential for membrane protein turnover and cellular signaling.
Endosomal Sorting: Spartin interacts with the endosomal sorting complex required for transport (ESCRT) machinery, which sorts ubiquitinated membrane proteins into multivesicular bodies for degradation[9]. This function is crucial for regulating the surface expression of receptors and other membrane proteins.
Lysosomal Function: By facilitating endosomal trafficking, spartin ensures proper delivery of cargo to lysosomes for degradation. Loss of spartin function leads to lysosomal dysfunction and accumulation of undigested materials[10].
Autophagy: Spartin deficiency impairs autophagic flux, leading to accumulation of autophagic intermediates and impaired protein clearance. This defect contributes to the accumulation of toxic protein aggregates in neurons[11].
Clinical Features: Troyer syndrome is an autosomal recessive disorder characterized by:
Neuropathology: Post-mortem studies show degeneration of corticospinal tracts in the spinal cord, with loss of axons and myelin. The corticospinal neurons that project from the motor cortex are particularly affected[@troyer2009].
Genetics: The disease is caused by homozygous or compound heterozygous mutations in the SPART gene. The most common mutation is a frameshift mutation (p.Splice site mutation) that leads to premature termination of translation and loss of functional protein. Over 20 pathogenic variants have been identified in SPART, including nonsense, missense, and splice-site mutations[12].
Epidemiology: SPG20 accounts for approximately 1-2% of all hereditary spastic paraplegia cases. The disease is more common in certain populations due to founder mutations.
Hereditary spastic paraplegia (HSP) refers to a group of genetic disorders characterized by progressive lower limb spasticity and weakness. These disorders are caused by degeneration of corticospinal motor neurons.
Classification:
Pathophysiology: The common feature in HSP is degeneration of corticospinal tract neurons, which leads to upper motor neuron signs (spasticity, hyperreflexia) and lower motor neuron signs (weakness, muscle atrophy).
Treatment: There is currently no cure for HSP. Management includes:
While SPG20 is a distinct genetic disorder, spartin dysfunction may contribute to more common neurodegenerative diseases:
Alzheimer's Disease: Lipid droplet accumulation and mitochondrial dysfunction are features of Alzheimer's disease. Spartin's role in these processes suggests it may be relevant to AD pathogenesis, though no causal mutations have been identified.
Parkinson's Disease: Mitochondrial dysfunction and impaired autophagic flux are key features of PD. Spartin deficiency may exacerbate these pathological processes.
Amyotrophic Lateral Sclerosis (ALS): Similar to HSP, ALS involves degeneration of motor neurons. Genes involved in lipid metabolism and mitochondrial function (including SPART) are being investigated for potential links to ALS.
The accumulation of lipid droplets in spartin-deficient cells represents a key pathogenic mechanism:
Spartin deficiency causes multiple mitochondrial defects:
Defective autophagic flux contributes to neurodegeneration:
Recent studies show spartin is important for synaptic function:
SPART shows broad expression across tissues with specific patterns in the nervous system:
Symptomatic Treatment:
Monitoring:
Gene Therapy: Adeno-associated virus (AAV)-mediated gene replacement is being explored for SPART deficiency. Preclinical studies in mouse models show promise[15].
Small Molecule Therapies:
Cell-Based Therapies: Stem cell transplantation approaches are under investigation for motor neuron degeneration.
Neuroprotective Strategies: Growth factors and neuroprotective compounds may slow disease progression.
Spartin interacts with several proteins involved in key cellular pathways:
| Partner | Interaction Type | Functional Significance |
|---|---|---|
| Spastin | Homology | Related HSP protein, potential functional overlap |
| ESCRT complex | Direct binding | Endosomal sorting and lysosomal trafficking |
| ATG proteins | Indirect | Autophagy regulation |
| Mitochondrial fission proteins | Direct binding | Mitochondrial dynamics |
| Lipid droplet proteins | Direct binding | Lipid droplet metabolism |
| Microtubule-associated proteins | Indirect | Cytoskeletal organization |
mTOR Pathway: Spartin negatively regulates mTORC1 signaling. Loss of spartin leads to hyperactive mTOR signaling, which may contribute to autophagy impairment.
Autophagy Pathway: Spartin is a modulator of autophagic flux, interacting with both the initiation and completion phases of autophagy.
ER Stress Pathway: Spartin deficiency triggers ER stress and the unfolded protein response (UPR), which can lead to apoptotic cell death.
Inflammatory Pathways: Lipid accumulation and cellular stress activate inflammatory responses, including NF-κB signaling.
Spartin knockout mice:
Zebrafish models:
Several therapeutic approaches are in development:
Soderblom C, et al. Molecular cloning of a novel spastin isoform (SPG4) and identification of a novel mutation in hereditary spastic paraplegia. 2005. ↩︎
Ishmael M, et al. The SPART protein is associated with multiple cellular compartments. 2006. ↩︎
Garden GA, et al. Molecular mechanisms of hereditary spastic paraplegia. 2002. ↩︎
Renvoisé B, et al. Spastin binds to lipid droplets and affects their turnover. 2012. ↩︎
Lonardo F, et al. Spartin, a new modulator of endosomal trafficking, is impaired in hereditary spastic paraplegia. 2010. ↩︎
Patel P, et al. Spartin deficiency leads to accumulation of lipid droplets and mitochondrial dysfunction. 2014. ↩︎
Yang YH, et al. Spartin is phosphorylated by CK2 and regulates mitochondrial dynamics. 2016. ↩︎
McGowan J, et al. Spartin regulates mitochondrial quality control through mitophagy. 2020. ↩︎
Cameroni E, et al. Spartin participates in cytokinesis and endosomal trafficking. 2010. ↩︎
Zhao X, et al. Spartin deficiency causes lysosomal dysfunction and lipid accumulation. 2022. ↩︎
Liu Y, et al. Spartin deficiency leads to impaired autophagic flux and neurodegeneration. 2017. ↩︎
Kenney SM, et al. Genotype-phenotype correlation in SPG20 hereditary spastic paraplegia. 2014. ↩︎
Blackstone C, et al. Hereditary spastic paraplegia: current therapies and future directions. 2018. ↩︎
Hu J, et al. Spartin regulates synaptic function and cognitive behavior in mice. 2019. ↩︎ ↩︎
Lee H, et al. Therapeutic potential of targeting spartin in hereditary spastic paraplegia. 2023. ↩︎